These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35238725)

  • 21. Efectiveness of belimumab in the treatment of lupus nephritis: analysis of 8 cases.
    de la Rubia Navarro M; Ivorra Cortés JR; Grau García E; Román Ivorra JA
    Med Clin (Barc); 2022 Oct; 159(7):344-346. PubMed ID: 35811138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.
    Plüß M; Piantoni S; Tampe B; Kim AHJ; Korsten P
    Hum Vaccin Immunother; 2022 Nov; 18(5):2072143. PubMed ID: 35588699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the treatment of systemic lupus erythematosus with belimumab in children.
    Deng WP
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1069-1074. PubMed ID: 34719425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes in lupus nephritis patients treated with belimumab in real-life setting: a retrospective comparative study in China.
    Lin Z; Jiang B; Wang W; Chen C; Wang Y; Wan J; Xu Y
    PeerJ; 2024; 12():e18028. PubMed ID: 39308826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus.
    Zhou X; Lee TI; Zhu M; Ma P
    Drugs R D; 2021 Dec; 21(4):407-417. PubMed ID: 34628605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
    Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
    Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Belimumab: review of use in systemic lupus erythematosus.
    Boyce EG; Fusco BE
    Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a novel autoinjector for subcutaneous self-administration of belimumab in systemic lupus erythematosus
.
    Sheikh SZ; Hammer AE; Fox NL; Groark J; Struemper H; Roth D; Gordon D
    Int J Clin Pharmacol Ther; 2016 Nov; 54(11):914-922. PubMed ID: 27668697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials.
    Gomez A; Jägerback S; Sjöwall C; Parodis I
    Rheumatology (Oxford); 2024 Feb; 63(2):338-348. PubMed ID: 37228028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.
    Struemper H; Thapar M; Roth D
    Clin Pharmacokinet; 2018 Jun; 57(6):717-728. PubMed ID: 28887801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Lupus; 2018 Jan; 27(1):112-119. PubMed ID: 28592201
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.
    Zhang K; Qi T; Guo D; Liu Y
    Immun Inflamm Dis; 2023 Jul; 11(7):e954. PubMed ID: 37506137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of belimumab in three cases of refractory lupus nephritis.
    Malaweera A; Dayan S; Pellicano R; Hoi A; Kitching AR; Kent JR
    Intern Med J; 2023 Oct; 53(10):1901-1906. PubMed ID: 37859540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S; Ehreiser L; Anders J; Anders HJ
    Front Immunol; 2022; 13():999704. PubMed ID: 36211360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
    Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.
    Wallace DJ; Atsumi T; Daniels M; Hammer A; Meizlik P; Quasny H; Schwarting A; Zhang F; Roth DA
    Lupus; 2022 Nov; 31(13):1649-1659. PubMed ID: 36206400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MOONLIGHT study: the design of a comparative study of the effectiveness of belimumab in patients with a history of lupus nephritis from the post-Marketed effectiveness of belimumab cOhOrt and JapaN Lupus NatIonwide reGistry (LUNA) coHorT.
    Sada K; Kurita N; Noma H; Matsuki T; Quasny H; Levy RA; Jones-Leone AR; Gairy K; Yajima N
    Lupus Sci Med; 2022 Sep; 9(1):. PubMed ID: 37017254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
    Margiotta DPE; Basta F; Batani V; Afeltra A
    BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis.
    Zhao L; Wang W; Wu L; Wu T; Tu J; Wu X; Sun F; Ding H; Shen N; Wu H; Zhu J; Sun L; Ye S
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38806217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.